GARD® technology.

GARD is a highly versatile genomic-based in vitro testing platform for assessment of various toxicological endpoints

GARD makes use of unique genomic biomarker signatures comprising genes involved in pathways known to be relevant to the toxicological outcome. Using the latest pattern recognition technology, the large volume of informational content provided by this approach enables mechanism-of-action based decisions, resulting in consistently high predictive accuracy.

Human Relevance

In short, a relevant dendritic like human cell-line is used as a model for the human immune system, which reacts differentially to allergenic stimulations compared to harmless substances.

Following cellular stimulation, the stimulatory agent can be classified according to its hazardous properties by evaluating a set of reporter probes, so-called genomic biomarkers.